[go: up one dir, main page]

WO2020022975A3 - New pharmaceutical compositions in the treatment of copd - Google Patents

New pharmaceutical compositions in the treatment of copd Download PDF

Info

Publication number
WO2020022975A3
WO2020022975A3 PCT/TR2018/000134 TR2018000134W WO2020022975A3 WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3 TR 2018000134 W TR2018000134 W TR 2018000134W WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pharmaceutical compositions
copd
new pharmaceutical
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/000134
Other languages
French (fr)
Other versions
WO2020022975A2 (en
Inventor
Mahmut Bi̇lgi̇ç
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutec Ar Ge Sanayi Ve Ticaret AS
Original Assignee
Neutec Ar Ge Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Ar Ge Sanayi Ve Ticaret AS filed Critical Neutec Ar Ge Sanayi Ve Ticaret AS
Publication of WO2020022975A2 publication Critical patent/WO2020022975A2/en
Publication of WO2020022975A3 publication Critical patent/WO2020022975A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising N-Acetycysteine and mannitol for use in the treatment of COPD attacks.
PCT/TR2018/000134 2017-12-29 2018-12-28 New pharmaceutical compositions in the treatment of copd Ceased WO2020022975A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/022950 2017-12-29
TR2017/22950A TR201722950A2 (en) 2017-12-29 2017-12-29 New pharmaceutical compositions in the treatment of COPD.

Publications (2)

Publication Number Publication Date
WO2020022975A2 WO2020022975A2 (en) 2020-01-30
WO2020022975A3 true WO2020022975A3 (en) 2020-02-27

Family

ID=67901361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/000134 Ceased WO2020022975A2 (en) 2017-12-29 2018-12-28 New pharmaceutical compositions in the treatment of copd

Country Status (2)

Country Link
TR (1) TR201722950A2 (en)
WO (1) WO2020022975A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800007928A1 (en) * 2018-08-07 2020-02-07 Sofar Spa Composition containing a mucolytic agent for the treatment of mucus hypersecretion and a device for its dosage
CN116098886B (en) * 2023-01-12 2024-04-26 澳门科技大学 Pharmaceutical composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
US20070065373A1 (en) * 2003-09-15 2007-03-22 Vectura Ltd. Mucoactive agents for treating a pulmonary disease
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065373A1 (en) * 2003-09-15 2007-03-22 Vectura Ltd. Mucoactive agents for treating a pulmonary disease
WO2006030221A1 (en) * 2004-09-15 2006-03-23 Cipla Limited Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ODZIOMEK, M. ET AL.: "Conception, preparation and properties of functional carrier particles for pulmonary drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 433, no. 1-2, 5 January 2012 (2012-01-05), pages 51 - 59, XP028493598 *
SNIJDERS, D. ET AL.: "Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 26, no. 2, pages 529 - 534, XP055687438 *
WEINBROUM, A. A. ET AL.: "Concomitant administration of mannitol and N-acetylcysteine for the prevention of lung reperfusion injury", JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, vol. 60, no. 6, 2006, pages 1290 - 1296, XP055687440 *

Also Published As

Publication number Publication date
TR201722950A2 (en) 2019-07-22
WO2020022975A2 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2015011898A (en) Pyrazolo compounds and uses thereof.
MX2022004304A (en) Apoptosis-inducing agents.
IL273959A (en) Methods and compositions for the treatment of rare diseases
MY187540A (en) Compounds active towards bromodomains
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
CL2016001231A1 (en) Autotaxin Inhibitor Compounds
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017004808A (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis.
CL2015002897A1 (en) Bace1 inhibitors
WO2018226992A8 (en) Tau aggregation inhibitors
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
IN2014MU00916A (en)
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
PH12016501838A1 (en) Compounds and their methods of use
PH12020550795A1 (en) Methods of using and compositions containing dulaglutide
EP3277269A4 (en) Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein
WO2020022975A3 (en) New pharmaceutical compositions in the treatment of copd
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
MA40642A (en) Novel peptide derivatives and uses thereof
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
PH12019500180A1 (en) Compositions for the treatment of pulmonary fibrosis
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18927968

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18927968

Country of ref document: EP

Kind code of ref document: A2